BRAF and melanoma: It was also speculated, based on in vitro studies, that melanoma-derived exosomes were also involved in resistance acquisition against BRAF inhibitors, with their participation mediated by the transport of resistance driver—platelet-derived growth factor β (PDGFRβ) to adjacent BRAF inhibitor sensitive cells [65] or by the melanocyte inducing transcription factor (MITF)-mediated upregulation of miR-211-5p, known to reduce sensitivity to BRAF inhibitors [174].